Similarly, knock down of CD39 by using a CD39 antisense oligonucleotide in vivo reduced the number of tumor-infiltrating CD39+ Tregs; as a consequence, the ratio of CD8+ T cells to Tregs in tumors was significantly improved [40]. The gene discussed is CD8A; the disease is neoplasm.